Literature DB >> 25500600

Pharmacologic management of adult breakthrough cancer pain.

Bruce Doulton1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25500600      PMCID： PMC4264807     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  19 in total

1.  Oral transmucosal fentanyl and sufentanil for incident pain.

Authors:  J Gardner-Nix
Journal:  J Pain Symptom Manage       Date:  2001-08       Impact factor: 3.612

Review 2.  Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.

Authors:  Frank Elsner; Giovambattista Zeppetella; Josep Porta-Sales; Ignacio Tagarro
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

3.  Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients.

Authors:  Katherine Webber; Andrew N Davies; Giovambattista Zeppetella; Martin R Cowie
Journal:  J Pain Symptom Manage       Date:  2014-04-22       Impact factor: 3.612

4.  Are there cost benefits to fentanyl for breakthrough pain?

Authors:  Mellar P Davis
Journal:  J Pain Symptom Manage       Date:  2012-09       Impact factor: 3.612

Review 5.  Fast-acting fentanyl preparations and pain management.

Authors:  K McWilliams; M Fallon
Journal:  QJM       Date:  2013-04-22

Review 6.  Cancer pain management: what's new?

Authors:  Jan Gaertner; Christine Schiessl
Journal:  Curr Pain Headache Rep       Date:  2013-04

Review 7.  The pharmacoeconomics of breakthrough cancer pain.

Authors:  Kuan-Ling Kuo; Surasak Saokaew; David D Stenehjem
Journal:  J Pain Palliat Care Pharmacother       Date:  2013-05-20

8.  The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen.

Authors:  Sebastiano Mercadante; Giovanna Prestia; Alessandra Casuccio
Journal:  Curr Med Res Opin       Date:  2013-08-19       Impact factor: 2.580

9.  Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.

Authors:  Neal E Slatkin; Fang Xie; John Messina; Thalia J Segal
Journal:  J Support Oncol       Date:  2007 Jul-Aug

10.  A survey of Canadian cancer patients' perspectives on the characteristics and treatment of breakthrough pain.

Authors:  Gillian Bedard; Philippa Hawley; Liying Zhang; Marissa Slaven; Pierre Gagnon; Stuart Bisland; Margaret Bennett; Francois Tardif; Edward Chow
Journal:  Support Care Cancer       Date:  2013-05-02       Impact factor: 3.603
View more
  2 in total

1.  Canadian recommendations for the management of breakthrough cancer pain.

Authors:  P Daeninck; B Gagnon; R Gallagher; J D Henderson; Y Shir; C Zimmermann; B Lapointe
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

2.  Sufentanil postoperative analgesia reduce the increase of T helper 17 (Th17) cells and FoxP3+ regulatory T (Treg) cells in rat hepatocellular carcinoma surgical model: A randomised animal study.

Authors:  Yanhua Peng; Jinfeng Yang; Duo Guo; Chumei Zheng; Huiping Sun; Qinya Zhang; Shuangfa Zou; Yanping Zhang; Ke Luo; Keith A Candiotti
Journal:  BMC Anesthesiol       Date:  2020-08-26       Impact factor: 2.217
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.